Inhibition of endothelial cell migration by thrombospondin-1 type-1 repeats is mediated by β1 integrins

Journal of Cell Biology

Volumn 168, Issue 4, 2005, Pages 643-653

  Short, Sarah M ^a   Derrien, Alexandrine ^a   Narsimhan, Radha P ^c   Lawler, Jack ^b   Ingber, Donald E ^a,b   Zetter, Bruce R ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1 INTEGRIN; CD36 ANTIGEN; MEMBRANE RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE C GAMMA; PROTEIN KINASE B; THROMBOSPONDIN 1; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL MIGRATION; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; MICROVASCULATURE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION; TYPE 1 REPEAT DOMAIN; UMBILICAL VEIN;

NON-PROGRAMMATIC;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTIGENS, CD29; ANTIGENS, CD36; CELL MOVEMENT; CELLS, CULTURED; ENDOTHELIAL CELLS; HUMANS; PHOSPHOLIPASE C; PHOSPHOLIPASE C GAMMA; PROTEIN STRUCTURE, TERTIARY; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; THROMBOSPONDIN 1; UMBILICAL VEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 13944267041     PISSN: 00219525     EISSN: None     Source Type: Journal    
DOI: 10.1083/jcb.200407060     Document Type: Article

References (67)

1. Adams, J.C., and J. Lawler. 2004. The thrombospondins. Int. J. Biochem. Cell Biol. 36:961-968.
2. Armulik, A., T. Veiling, and S. Johansson. 2004. The integrin β1 subunit transmembrane domain regulates phosphatidylinositol 3-kinase-dependent tyrosine phosphorylation of Crk-associated substrate. Mol. Biol. Cell. 15:2558-2567.
3. Asch, A.S., S. Silbiger, E. Heimer, and R.L. Nachman. 1992. Thrombospondin sequence motif (CSVTCG) is responsible for CD36 binding. Biochem. Biophys. Res. Commun. 182:1208-1217.
4. Berrier, A.L., A.M. Mastrangelo, J. Downward, M. Ginsberg, and S.E. La-Flamme. 2000. Activated R-ras, Racl, PI 3-kinase and PKCε can each restore cell spreading inhibited by isolated integrin β1 cytoplasmic domains. J. Cell Biol. 151:1549-1560.
5. Bjorndahl, M., R. Cao, A. Eriksson, and Y. Cao. 2004. Blockage of VEGF-induced angiogenesis by preventing VEGF secretion. Circ. Res. 94:1443-1450.
6. Bornstein, P. 2001. Thrombospondins as matricellular modulators of cell function. J. Clin. Invest. 107:929-934.
7. Brooks, P.C., R.A. Clark, and D.A. Cheresh. 1994. Requirement of vascular integrin αvβ3 for angiogenesis. Science. 264:569-571.
8. Calzada, M.J., D.S. Annis, B. Zeng, C. Marcinkiewicz, B. Banas, J. Lawler, D.F. Mosher, and D.D. Roberts. 2004a. Identification of novel β1 integrin binding sites in the type 1 and type 2 repeats of thrombospondin-1. J. Biol. Chem. 279:41734-41743.
9. Calzada, M.J., L. Zhou, J.M. Sipes, J. Zhang, H.C. Krutzsch, M.L. Iruela-Arispe, D.S. Annis, D.F. Mosher, and D.D. Roberts. 2004b. α4β1 integrin mediates selective endothelial cell responses to thrombospondins 1 and 2 in vitro and modulates angiogenesis in vivo. Circ. Res. 94:462-470.
10. Campbell, S.C., O.V. Volpert, M. Ivanovich, and N.P. Bouck. 1998. Molecular mediators of angiogenesis in bladder cancer. Cancer Res. 58:1298-1304.
11. Chandrasekaran, L., C.Z. He, H. Al-Barazi, H.C. Krutzsch, M.L. Iruela-Arispe, and D.D. Roberts. 2000. Cell contact-dependent activation of α3β1 integrin modulates endothelial cell responses to thrombospondin-1. Mol. Biol. Cell. 11:2885-2900.
12. Chen, H., M.E. Herndon, and J. Lawler. 2000. The cell biology of thrombospondin-1. Matrix Biol. 19:597-614.
13. Cheng, Y.F., R.I. Clyman, J. Enenstein, N. Waleh, R. Pytela, and R.H. Kramer. 1991. The integrin complex αvβ3 participates in the adhesion of microvascular endothelial cells to fibronectin. Exp. Cell Res. 194:69-77.
14. Clyman, R.I., F. Mauray, and R.H. Kramer. 1992. β1 and β3 integrins have different roles in the adhesion and migration of vascular smooth muscle cells on extracellular matrix. Exp. Cell Res. 200:272-284.
15. Dal Canto, R.A., M.K. Shaw, G.P. Nolan, L. Steinman, and C.G. Fathman. 1999. Local delivery of TNF by retrovirus-transduced T lymphocytes exacerbates experimental autoimmune encephalomyelitis. Clin. Immunol. 90:10-14.
16. Dawson, D.W., S.F. Pearce, R. Zhong, R.L. Silverstein, W.A. Frazier, and N.P. Bouck. 1997. CD36 mediates the In vitro inhibitory effects of thrombospondin-1 on endothelial cells. J. Cell Biol. 138:707-717.
17. Dawson, D.W., O.V. Volpert, S.F. Pearce, A.J. Schneider, R.L. Silverstein, J. Henkin, and N.P. Bouck. 1999. Three distinct D-amino acid substitutions confer potent antiangiogenic activity on an inactive peptide derived from a thrombospondin-1 type 1 repeat. Mol. Pharmacol. 55:332-338.
18. Dimmeler, S., E. Dernbach, and A.M. Zeiher. 2000. Phosphorylation of the endothelial nitric oxide synthase at ser-1177 is required for VEGF-induced endothelial cell migration. FEBS Lett. 477:258-262.
19. Doll, J.A., F.K. Reiher, S.E. Crawford, M.R. Pins, S.C. Campbell, and N.P. Bouck. 2001. Thrombospondin-1, vascular endothelial growth factor and fibroblast growth factor-2 are key functional regulators of angiogenesis in the prostate. Prostate. 49:293-305.
20. Ferrara, N. 2004. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist. 9(Suppl 1):2-10.
21. Folkman, J. 1995. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1:27-31.
22. Friedlander, M., P.C. Brooks, R.W. Shaffer, C.M. Kincaid, J.A. Varner, and D.A. Cheresh. 1995. Definition of two angiogenic pathways by distinct αv integrins. Science. 270:1500-1502.
23. Gerber, H.P., A. McMurtrey, J. Kowalski, M. Yan, B.A. Keyt, V. Dixit, and N. Ferrara. 1998. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J. Biol. Chem. 273:30336-30343.
24. Good, D.J., P.J. Polverini, F. Rastinejad, M.M. Le Beau, R.S. Lemons, W.A. Frazier, and N.P. Bouck. 1990. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc. Natl. Acad. Sci. USA. 87:6624-6628.
25. Green, J.M., A. Zhelesnyak, J. Chung, F.P. Lindberg, M. Sarfati, W.A. Frazier, and E.J. Brown. 1999. Role of cholesterol in formation and function of a signaling complex involving αvβ3, integrin-associated protein (CD47), and heterotrinieric G proteins. J. Cell Biol. 146:673-682.
26. Howe, A., A.E. Aplin, S.K. Alahari, and R.L. Juliano. 1998. Integrin signaling and cell growth control. Curr. Opin. Cell Biol. 10:220-231.
27. Hynes, R.O., J.C. Lively, J.H. McCarty, D. Taverna, S.E. Francis, K. Hodivala-Dilke, and Q. Xiao. 2002. The diverse roles of integrins and their ligands in angiogenesis. Cold Spring Harb. Symp. Quant. Biol. 67:143-153.
28. Ingber, D.E. 1990. Fibronectin controls capillary endothelial cell growth by modulating cell shape. Proc. Natl. Acad. Sci. USA. 87:3579-3583.
29. Iruela-Arispe, M.L., M. Lombardo, H.C. Krutzsch, J. Lawler, and D.D. Roberts. 1999. Inhibition of angiogenesis by thrombospondin-1 is mediated by 2 independent regions within the type 1 repeats. Circulation. 100:1423-1431.
30. Jimenez, B., O.V. Volpert, S.E. Crawford, M. Febbraio, R.L. Silverstein, and N. Bouck. 2000. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat. Med. 6:41-48.
31. Kanda, S., T. Shono, B. Tomasini-Johansson, P. Klint, and Y. Saito. 1999. Role of thrombospondin-1-derived peptide, 4N1K, in FGF-2-induced angiogenesis. Exp. Cell Res. 252:262-272.
32. Kim, S., K. Bell, S.A. Mousa, and J.A. Varner. 2000. Regulation of angiogenesis in vivo by ligation of integrin α5β1 with the central cell-binding domain of fibronectin. Am. J. Pathol. 156:1345-1362.
33. Kumar, S., and C. Li. 2001. Targeting of vasculature in cancer and other angiogenic diseases. Trends Immunol. 22:129.
34. Laderoute, K.R., R.M. Alarcon, M.D. Brody, J.M. Calaoagan, E.Y. Chen, A.M. Knapp, Z. Yun, N.C. Denko, and A.J. Giaccia. 2000. Opposing effects of hypoxia on expression of the angiogenic inhibitor thrombospondin 1 and the angiogenic inducer vascular endothelial growth factor. Clin. Cancer Res. 6:2941-2950.
35. Lawler, J. 2002. Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. J. Cell. Mol. Med. 6:1-12.
36. Maeshima, Y., M. Manfredi, C. Reimer, K.A. Holthaus, H. Hopfer, B.R. Chandamuri, S. Kharbanda, and R. Kalluri. 2001. Identification of the antiangiogenic site within vascular basement membrane-derived tumstatin. J. Biol. Chem. 276:15240-15248.
37. Meredith, J.E., Jr., B. Fazeli, and M.A. Schwartz. 1993. The extracellular matrix as a cell survival factor. Mol. Biol. Cell. 4:953-961.
38. Miao, W.M., W.L. Seng, M. Duquette, P. Lawler, C. Laus, and J. Lawler. 2001. Thrombospondin-1 type 1 repeat recombinant proteins inhibit tumor growth through transforming growth factor-β-dependent and -independent mechanisms. Cancer Res. 61:7830-7839.
39. Miller, L.A., J.J. Hong, M.S. Kinch, M.L. Harrison, and R.L. Geahlen. 1999. The engagement of β1 integrins on promonocytic cells promotes phosphorylation of Syk and formation of a protein complex containing Lyn and β1 integrin. Eur. J. Immunol. 29:1425-1434.
40. Miyamoto, S., H. Teramoto, J.S. Gutkind, and K.M. Yamada. 1996. Integrins can collaborate with growth factors for phosphorylation of receptor tyrosine kinases and MAP kinase activation: roles of integrin aggregation and occupancy of receptors. J. Cell Biol. 135:1633-1642.
41. Murillo, C.A., P.G. Rychahou, and B.M. Evers. 2004. Inhibition of α5 integrin decreases PI3K activation and cell adhesion of human colon cancers. Surgery. 136:143-149.
42. Nguyen, M., Y. Shing, and J. Folkman. 1994. Quantitation of angiogenesis and antiangiogenesis in the chick embryo chorioallantoic membrane. Microvasc. Res. 47:31-40.
43. Plopper, G., and D.E. Ingber. 1993. Rapid induction and isolation of focal adhesion complexes. Biochem. Biophys. Res. Commun. 193:571-578.
44. Qi, J.H., and L. Claesson-Welsh. 2001. VEGF-induced activation of phosphoinositide 3-kinase is dependent on focal adhesion kinase. Exp. Cell Res. 263:173-182.
45. 3 mRNA stability. Mol. Biol. Cell. 12:3126-3138.
46. Reyes-Reyes, M., N. Mora, A. Zentella, and C. Rosales. 2001. Phosphatidylinositol 3-kinase mediates integrin-dependent NF-κB and MAPK activation through separate signaling pathways. J. Cell Sci. 114:1579-1589.
47. Ribatti, D., A. Vacca, and M. Presta. 2000. The discovery of angiogenic factors: a historical review. Gen. Pharmacol. 35:227-231.
48. Salicioni, A.M., A. Gaultier, C. Brownlee, M.K. Cheezum, and S.L. Gonias. 2004. Low density lipoprotein receptor-related protein-1 promotes β1 integrin maturation and transport to the cell surface. J. Biol. Chem. 279:10005-10012.
49. Short, S.M., G.A. Talbott, and R.L. Juliano. 1998. Integrin-mediated signaling events in human endothelial cells. Mol. Biol. Cell. 9:1969-1980.
50. Shuster, C.B., and I.M. Herman. 1998. The mechanics of vascular cell motility. Microcirculation. 5:239-257.
51. Sudhakar, A., H. Sugimoto, C. Yang, J. Lively, M. Zeisberg, and R. Kalluri. 2003. Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by αvβ3 and α5β1 integrins. Proc. Natl. Acad. Sci. USA. 100:4766-4771.
52. Swerlick, R.A., K.H. Lee, T.M. Wick, and T.J. Lawley. 1992. Human dermal microvascular endothelial but not human umbilical vein endothelial cells express CD36 in vivo and in vitro. J. Immunol. 148:78-83.
53. Tan, K., M. Duquette, J.H. Liu, Y. Dong, R. Zhang, A. Joachimiak, J. Lawler, and J.H. Wang. 2002. Crystal structure of the TSP-1 type 1 repeats: a novel layered fold and its biological implication. J. Cell Biol. 159:373-382.
54. Thakker, G.D., D.P. Hajjar, W.A. Muller, and T.K. Rosengart. 1999. The role of phosphatidylinositol 3-kinase in vascular endothelial growth factor signaling. J. Biol. Chem. 274:10002-10007.
55. Tolsma, S.S., J.D. Cohen, L.S. Ehrlich, and N.P. Bouck. 1993a. Transformation of NIH/3T3 to anchorage independence by H-ras is accompanied by loss of suppressor activity. Exp. Cell Res. 205:232-239.
56. Tolsma, S.S., O.V. Volpert, D.J. Good, W.A. Frazier, P.J. Polverini, and N. Bouck. 1993b. Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. J. Cell Biol. 122:497-511.
57. Tsou, R., and F.F. Isik. 2001. Integrin activation is required for VEGF and FGF receptor protein presence on human microvascular endothelial cells. Mol. Cell. Biochem. 224:81-89.
58. Vogel, T., N.H. Guo, H.C. Krutzsch, D.A. Blake, J. Hartman, S. Mendelovitz, A. Panet, and D.D. Roberts. 1993. Modulation of endothelial cell proliferation, adhesion, and motility by recombinant heparin-binding domain and synthetic peptides from the type I repeats of thrombospondin. J. Cell. Biochem. 53:74-84.
59. Volpert, O.V., J. Lawler, and N.P. Bouck. 1998. A human fibrosarcoma inhibits systemic angiogenesis and the growth of experimental metastases via thrombospondin-1. Proc. Natl. Acad. Sci. USA. 95:6343-6348.
60. Watnick, R.S., Y.N. Cheng, A. Rangarajan, T.A. Ince, and R.A. Weinberg. 2003. Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis. Cancer Cell. 3:219-231.
61. Wickstrom, S.A., K. Alitalo, and J. Keski-Oja. 2002. Endostatin associates with integrin α5β1 and caveolin-1, and activates Src via a tyrosyl phosphatase-dependent pathway in human endothelial cells. Cancer Res. 62:5580-5589.
62. Wickstrom, S.A., K. Alitalo, and J. Keski-Oja. 2004. An endostatin-derived peptide interacts with integrins and regulates actin cytoskeleton and migration of endothelial cells. J. Biol. Chem. 279:20178-20185.
63. Woods, M.L., W.J. Kivens, M.A. Adelsman, Y. Qiu, A. August, and Y. Shimizu. 2001. A novel function for the Tec family tyrosine kinase Itk in activation of β1 integrins by the T-cell receptor. EMBO J. 20:1232-1244.
64. Yoshida, A., B. Anand-Apte, and B.R. Zetter. 1996. Differential endothelial migration and proliferation to basic fibroblast growth factor and vascular endothelial growth factor. Growth Factors. 13:57-64.
65. Zachary, I., and G. Gliki. 2001. Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovasc. Res. 49:568-581.
66. Zeng, H., H.F. Dvorak, and D. Mukhopadhyay. 2001. Vascular permeability factor (VPF)/vascular endothelial growth factor (VEGF) receptor-1 down-modulates VPF/VEGF receptor-2-mediated endothelial cell proliferation, but not migration, through phosphatidylinositol 3-kinase-dependent pathways. J. Biol. Chem. 276:26969-26979.
67. Zetter, B.R. 1980. Migration of capillary endothelial cells is stimulated by tumour-derived factors. Nature. 285:41-43.